Holen Sie sich die Stockscreener-App
0.9489
12.30%
0.1039
Handel nachbörslich:
.95
0.0011
+0.12%
Schlusskurs vom Vortag:
$0.845
Offen:
$0.851
24-Stunden-Volumen:
30,456
Relative Volume:
0.41
Marktkapitalisierung:
$11.23M
Einnahmen:
$248.40K
Nettoeinkommen (Verlust:
$-3.05M
KGV:
-3.6342
EPS:
-0.2611
Netto-Cashflow:
$-3.30M
1W Leistung:
+15.54%
1M Leistung:
-6.97%
6M Leistung:
-6.97%
1J Leistung:
-46.81%
1-Tages-Spanne:
$0.80
$0.949
1-Wochen-Bereich:
$0.7773
$0.949
52-Wochen-Spanne:
$0.6801
$3.68
Cytomed Therapeutics Ltd Stock (GDTC) Company Profile
Firmenname
Cytomed Therapeutics Ltd
Sektor
Branche
Telefon
-
Adresse
-
Compare GDTC vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GDTC
Cytomed Therapeutics Ltd
|
0.9489 | 9.57M | 248.40K | -3.05M | -3.30M | -0.2611 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cytomed Therapeutics Ltd Aktie (GDTC) Neueste Nachrichten
CytoMed Therapeutics Ltd SEC Filing (Aug 11, 2026) - Stock Titan
CytoMed Therapeutics Ltd (GDTC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CytoMed Therapeutics Ltd (GDTC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CytoMed Therapeutics Ltd (GDTC) Institutional Confidence - TradingKey
GDTC|CytoMed Therapeutics Ltd|Price:0.880|Chg%:-0.110 - TradingKey
CytoMed Therapeutics Ltd (GDTC) Cash Flow - TradingKey
CytoMed Therapeutics Ltd (GDTC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CytoMed Therapeutics Ltd (GDTC) Balance Sheet - TradingKey
CytoMed Therapeutics Ltd (GDTC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CytoMed Therapeutics Ltd (GDTC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CytoMed Therapeutics Ltd (GDTC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CytoMed Therapeutics Ltd (GDTC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GDTC|CytoMed Therapeutics Ltd|Price:0.990|Chg%:+0.140 - TradingKey
CytoMed Therapeutics Ltd (GDTC) Valuation: PE, PB & Fair Value Analysis - TradingKey
CytoMed Therapeutics Ltd (GDTC) Income Statement - TradingKey
Form 13D/A CytoMed Therapeutics Ltd For: 24 July By Investing.com - Investing.com South Africa
CytoMed Therapeutics (GDTC) director adds 200,000 shares in July buys - Stock Titan
Form 4 CytoMed Therapeutics Ltd For: 24 July By Investing.com - Investing.com South Africa
CytoMed Therapeutics (GDTC) insider discloses two ordinary share dispositions - Stock Titan
CytoMed Therapeutics' US$1.7m Market Cap Fall Books Insider Losses - simplywall.st
CytoMed Therapeutics Ltd – An Emerging Star in Singapore’s Cancer Biotechnology Sector - FinancialContent
CytoMed Therapeutics(GDTC) Stock Options Chain | Quotes & News - Moomoo
CytoMed Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting) - Moomoo
CytoMed Therapeutics (GDTC) Stock Forecast & Analyst Ratings - Moomoo
CytoMed Therapeutics Ltd (NASDAQ: GDTC) – A Rising Star in Singapore’s Cancer Biotechnology Sector - FinancialContent
GDTCCytoMed Therapeutics Ltd Options - Finviz
CytoMed, a Singapore Biotech, RevolutionizesCancer Treatment Using Donor Immune Cells - openPR.com
CytoMed Chairman Boosts Personal Stake and Funds R&D Expansion at LongevityBank - The Globe and Mail
Form 6K CytoMed Therapeutics Ltd For: 23 June - Investing.com UK
Form 6K CytoMed Therapeutics Ltd For: 23 June By Investing.com - Investing.com Australia
CytoMed Therapeutics (NASDAQ: GDTC) chair ups exposure and funds LongevityBank R&D - Stock Titan
CytoMed Therapeutics (NASDAQ: GDTC) director buys 112,000 shares in open market - Stock Titan
CytoMed Therapeutics (NASDAQ: GDTC) shareholders approve all AGM proposals - Stock Titan
CytoMed Therapeutics (GDTC) Dips 2.48% as Key Support at $1.08 Comes into FocusDouble Top - newsline.com
CytoMed Therapeutics (NASDAQ: GDTC) director discloses holding 4,000 Ordinary Shares - Stock Titan
CytoMed Therapeutics LtdA Rising Star in Singapore's Cancer Biotechnology Sector - openPR.com
CytoMed Therapeutics Limited is accelerating its international expansion - openPR.com
CytoMed Therapeutics (NASDAQ: GDTC) director reports 2,469 ordinary shares on Form 3 - Stock Titan
CytoMed Therapeutics (NASDAQ: GDTC) director files initial Form 3 ownership - Stock Titan
CytoMed Therapeutics (NASDAQ: GDTC) director Choo Chee Kong details direct and indirect share ownership - Stock Titan
CytoMed Therapeutics (NASDAQ: GDTC) CFO reports holding 25,781 ordinary shares - Stock Titan
CytoMed Therapeutics (GDTC) chair adds 112,000 shares in private purchase - Stock Titan
[144] CytoMed Therapeutics Ltd SEC Filing - Stock Titan
Finanzdaten der Cytomed Therapeutics Ltd-Aktie (GDTC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):